4-(4'-Hydroxymethyl-biphenyl-2-yl)-piperazine-1-carboxylic acid tert-butyl ester | 735333-44-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4'-Hydroxymethyl-biphenyl-2-yl)-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 4-[2-[4-(hydroxymethyl)phenyl]phenyl]piperazine-1-carboxylate
• CAS: 735333-44-5
• 化学式: C₂₂H₂₈N₂O₃
• 分子量: 368.476
• InChiKey: QUSSCMCGBOXWBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  53
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(4'-Hydroxymethyl-biphenyl-2-yl)-piperazine-1-carboxylic acid tert-butyl ester 、 甲基磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.67h， 以100%的产率得到4-(4'-Methanesulfonyloxymethyl-biphenyl-2-yl)-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  5HT7 Antagonists and inverse agonists

  摘要：

  本发明涉及公式I的化合物及其药用盐。这些化合物可用作心理治疗药物。

  公开号：

  US20040229874A1
• 作为产物：
  描述：

  4-(4'-Formyl-biphenyl-2-yl)-piperazine-1-carboxylic acid tert-butyl ester 在 lithium aluminium tetrahydride 、 sodium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 0.25h， 以61%的产率得到4-(4'-Hydroxymethyl-biphenyl-2-yl)-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  5HT7 Antagonists and inverse agonists

  摘要：

  本发明涉及公式I的化合物及其药用盐。这些化合物可用作心理治疗药物。

  公开号：

  US20040229874A1

文献信息

• Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotein and metalloenzyme targets
  申请人：——

  公开号：US20030225155A1

  公开（公告）日：2003-12-04

  The invention relates to the treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, immunological diseases, transplanted organ rejection, and diseases produced by intoxication with heavy metals. The invention relates to the use of specific metal chelating agents including, furoic acid, 2-thiophenecarboxylic acid and their derivatives, analogs and structurally related chemicals as pharmacological agents that can be used effectively to disrupt and inactivate specific transition metal ion containing zinc finger structural motifs in metalloproteins and specific transition metal ion containing catalytic sites in metalloproteinases, which in turn, inactivate the pathogenic virus, pathogenic prokaryotic or eukaryotic cells which produces disease conditions. The preparations can be administered topically or for systemic use. The preparations are novel wide-spectrum antibiotics which have antiviral, antiproliferative, antineoplastic, antiangiogenic, antibacterial, antiparasitic, antiinfective, and anti-inflammatory effects and can be used in the treatment and prevention of diseases such as AIDS, cancers, untoward angiogenesis, pulmonary anthrax, malaria, inflammatory responses, Alzheimer's disease and other diseases.

  该发明涉及治疗病毒性、细菌性、寄生虫性、增殖性疾病、神经退行性疾病、炎症性疾病、免疫性疾病、移植器官排斥反应以及由重金属中毒引起的疾病。该发明涉及使用特定的金属螯合剂，包括呋酸、2-噻吩羧酸及其衍生物、类似物和结构相关化学物质作为药理剂，可以有效地干扰和失活金属蛋白中含锌指结构基序和金属蛋白酶中含有特定过渡金属离子的催化位点，从而失活致病病毒、致病的原核或真核细胞，这些细胞会产生疾病症状。这些制剂可以局部或全身使用。这些制剂是新型广谱抗生素，具有抗病毒、抗增殖、抗肿瘤、抗血管生成、抗细菌、抗寄生虫、抗感染和抗炎症作用，可用于治疗和预防艾滋病、癌症、不良血管生成、肺炭疽、疟疾、炎症反应、阿尔茨海默病等疾病。
• Pharmacological agents and methods of treatment that inactivate pathogenic prokaryotic and eukaryotic cells and viruses by attacking highly conserved domains in structural metalloprotien and metalloenzyme targets
  申请人：——

  公开号：US20040167204A1

  公开（公告）日：2004-08-26

  The invention relates to the treatment of viral, bacterial, parasitic, proliferative diseases, neurodegenerative diseases, inflammatory diseases, immunological diseases, transplanted organ rejection, and diseases produced by intoxication with heavy metals. The invention relates to the use of specific metal chelating agents including, furoic acid, 2-thiophenecarboxylic acid and their derivatives, analogs and structurally related chemicals as pharmacological agents that can be used effectively to disrupt and inactivate specific transition metal ion containing zinc finger structural motifs in metalloproteins and specific transition metal ion containing catalytic sites in metalloproteinases, which in turn, inactivate the pathogenic virus, pathogenic prokaryotic or eukaryotic cells which produces disease conditions. The preparations can be administered topically or for systemic use. The preparations are novel wide-spectrum antibiotics which have antiviral, antiproliferative, antineoplastic, antiangiogenic, antibacterial, antiparasitic, antiinfective, and anti-inflammatory effects and can be used in the treatment and prevention of diseases such as AIDS, cancers, untoward angiogenesis, pulmonary anthrax, malaria, inflammatory responses, Alzheimer's disease and other diseases.

  本发明涉及病毒、细菌、寄生虫、增殖性疾病、神经退行性疾病、炎症性疾病、免疫性疾病、移植器官排斥以及重金属中毒引起的疾病的治疗。本发明涉及特定金属螯合剂的使用，包括呋喃酸、2-噻吩甲酸及其衍生物、类似物和结构相关的化学物质作为药剂，可有效用于破坏金属蛋白中含有锌指结构基团的特定过渡金属离子和金属蛋白酶中含有催化位点的特定过渡金属离子并使其失活，进而使致病病毒、致病原核细胞或真核细胞失活，从而产生疾病。制剂可局部或全身使用。这些制剂是新型广谱抗生素，具有抗病毒、抗增殖、抗肿瘤、抗血管生成、抗菌、抗寄生虫、抗感染和抗炎作用，可用于治疗和预防艾滋病、癌症、血管意外生成、肺炭疽、疟疾、炎症反应、老年痴呆症等疾病。
• 5HT7 ANTAGONISTS AND INVERSE AGONISTS
  申请人：Pfizer Products Incorporated

  公开号：EP1592772A2

  公开（公告）日：2005-11-09
• US6803379B2
  申请人：——

  公开号：US6803379B2

  公开（公告）日：2004-10-12
• [EN] 5HT7 ANTAGONISTS AND INVERSE AGONISTS<br/>[FR] ANTAGONISTES 5HT7 ET AGONISTES INVERSES
  申请人：PFIZER PROD INC

  公开号：WO2004067703A2

  公开（公告）日：2004-08-12

  The present invention relates to compounds of formula (I), and the pharmaceutically acceptable salts thereof. These compounds are useful as psychotherapeutic agents.